Petrelintide

Petrelintide is a long-acting synthetic amylin analog being developed for chronic weight management. It is administered as once-weekly subcutaneous injection. The compound mimics endogenous amylin, a peptide co-secreted with insulin from pancreatic beta cells in response to nutrient intake. It is being co-developed and co-commercialized by Zealand Pharma and Roche under a March 2025 collaboration agreement worth up to $5.3 billion. The compound is in late Phase 2 development with Phase 3 trials planned to begin in the second half of 2026. It is not yet approved by any regulator.

The molecule was discovered through Zealand Pharma's peptide drug discovery platform. Roche acquired the co-development and co-commercialization rights through the March 2025 deal, which included $1.65 billion upfront payment. The deal also covers combination products of petrelintide with CT-388, Roche's lead incretin asset (a GLP-1/GIP receptor dual agonist).

The structural design emphasizes:

Long-acting pharmacokinetics suitable for once-weekly subcutaneous administration. The modifications protect against rapid amylin degradation.

Chemical and physical stability with no fibrillation around neutral pH. Amylin is normally prone to amyloid fibrillation, which has been a structural problem for previous amylin therapeutics. The petrelintide design specifically addresses this through structural modifications that maintain solubility and stability.

Co-formulation potential. The chemical stability allows co-formulation with other peptides, which is the basis for the planned combination products with CT-388 and potentially other incretin agents.

The ZUPREME-1 Phase 2 Evidence

The ZUPREME-1 trial is the primary Phase 2 evidence for petrelintide.

Trial design. Randomized, double-blind, placebo-controlled, parallel-group, multinational Phase 2 trial. ClinicalTrials.gov NCT06662539. 493 participants with overweight or obesity (mean BMI of 37 kg/m²) in a gender-balanced trial population. Five target doses of petrelintide up to 9 mg over 42 weeks.

Primary endpoint. Body weight reduction at week 28. All five treatment arms achieved statistically significant weight reduction versus placebo (p<0.001).

Week 42 results. Mean body weight reduction of up to 10.7 percent versus 1.7 percent with placebo. Maximum response at the higher dose levels. Statistically significant and clinically meaningful weight loss.

Tolerability findings (the distinguishing feature). "Placebo-like tolerability" with discontinuation rates due to adverse events of 4.8 percent in the maximally effective arm versus 4.9 percent for placebo. No cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events at the maximally effective dose. This is the central marketing claim and the structural advantage over GLP-1 agonists, which produce substantial GI side effects.

Placebo-like safety profile. The safety data established petrelintide as strikingly well-tolerated, particularly in contrast to GLP-1 class agents where 20 to 30 percent of patients experience clinically meaningful GI side effects.

Petrelintide acts on the calcitonin receptor system (calcitonin receptor plus RAMP proteins forming amylin receptors AMY1, AMY2, AMY3) with the same fundamental mechanism as native amylin and cagrilintide.

Amylin receptor activation in the brain. The area postrema (brainstem nausea center) and hypothalamic feeding centers express amylin receptors. Activation produces appetite suppression and earlier satiation.

Slowed gastric emptying. Postprandial gastric retention reduces meal size by extending the duration of satiety signals. The effect is similar in concept to but mechanistically distinct from GLP-1's gastric emptying effects.

Reduced glucagon secretion. Amylin acts on pancreatic alpha cells to suppress glucagon release, contributing to better postprandial glucose control.

Leptin sensitivity restoration. Amylin signaling restores sensitivity to leptin (the long-term adipose-tissue satiety hormone). This is one of the mechanisms believed to underlie the sustained weight-loss effects of amylin analogs.

Mechanism distinction from GLP-1 agonists. GLP-1 agonists activate the GLP-1 receptor for appetite suppression and incretin effects. Amylin agonists activate the amylin receptor system for satiety modulation. The two pathways are complementary, which is the basis for combination approaches like cagrilintide+semaglutide (CagriSema) and the planned petrelintide+CT-388 combination.

The pharmacokinetic profile supports once-weekly subcutaneous administration. Dose escalation in the ZUPREME-1 trial used every-fourth-week dose increases up to 9 mg maximum dose.

Regulatory status

United States and Europe. Phase 2 complete (ZUPREME-1, March 2026). Phase 3 development planned for the second half of 2026. No FDA or EMA approval. NDA/MAA submissions anticipated approximately 2028 to 2029 based on standard Phase 3 timelines.

Combination programs. Phase 2 trial of petrelintide+CT-388 planned for first half of 2026. Regulatory pathway for combination products follows the standard fixed-dose combination route.

Commercial structure. Zealand Pharma has co-development and co-commercialization rights with Roche in the US and Europe. The structure resembles the Boehringer Ingelheim/Zealand survodutide collaboration but with broader Zealand involvement in commercialization.

WADA status. Petrelintide is not currently named on the WADA Prohibited List. The amylin mechanism does not directly support sport performance. The compound would likely fall under section S4 (Hormone and Metabolic Modulators) if specifically reviewed.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The ZUPREME-1 Phase 2 safety profile is the strongest part of the petrelintide evidence base.

Placebo-like tolerability. Overall adverse event rates were similar to placebo at the maximally effective dose.

No vomiting cases at the maximally effective dose. Zero. This is a striking finding given that vomiting is among the most common adverse events with GLP-1 agonists.

No treatment discontinuations due to gastrointestinal adverse events at the maximally effective dose.

Discontinuation rates of 4.8 percent at the maximally effective dose versus 4.9 percent placebo.

Mild nausea at lower rates than GLP-1 agonists, often transient during dose escalation.

Injection-site reactions at low rates.

The favorable tolerability profile is the central commercial advantage and the basis for the "redefine the weight management experience" marketing claim. Whether the tolerability advantage holds in larger Phase 3 trials and in real-world use will determine the commercial positioning.

The two amylin analog programs are the most direct competitors in the post-incretin obesity development space.

Petrelintide (Zealand/Roche). Phase 2 ZUPREME-1: 10.7 percent weight loss at 42 weeks. "Placebo-like tolerability." Phase 3 planned H2 2026.

Cagrilintide (Novo Nordisk). Phase 3 REDEFINE-1: 11.8 percent weight loss at 68 weeks as monotherapy. The combination CagriSema (cagrilintide + semaglutide) reported 23 percent weight loss in the same trial. NDA submitted December 18, 2025.

The two compounds have similar mechanism class and similar monotherapy efficacy. Cagrilintide is approximately 12 to 18 months ahead in regulatory timing. Petrelintide has the stronger tolerability claim. The competitive positioning will depend on whether the tolerability advantage translates to commercial differentiation in actual clinical use, and whether the petrelintide+CT-388 combination produces effects comparable to CagriSema or better.

The amylin class as a whole represents the most significant mechanism expansion in obesity pharmacotherapy beyond the incretin family. Whether dual GLP-1/glucagon (mazdutide/survodutide), triple agonists (retatrutide), or amylin/incretin combinations (CagriSema, petrelintide+CT-388) dominate the next phase of obesity therapy depends on Phase 3 readouts in 2026 to 2028.